Globally, our findings demonstrated that GBM, particularly the GSC subpopulation, is sensitive to glycolytic inhibition, and shed light on the therapeutic potential of LDH-A inhibitors in this tumour, which is characterised by a poor prognosis. Here, LDHA is linked to glioblastoma.